Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|October 9, 2014
Quintiles Exec Makes Case to Congress for Reducing Clinical Trial Timelines
Cohen addresses the three-pronged parts of drug development process or clinical trials
Advertisement
Quintiles released the written remarks, its Senior Vice President and Global Head of Early Clinical Development, Oren Cohen, MD, will make today October 9, to a Congressional Roundtable being held in Research Triangle Park, NC. The roundtable is an outgrowth of the U.S. House Energy & Commerce Committee’s
In these remarks, again specific to vaccines, Cohen addresses the three-pronged parts of drug development process or clinical trials; pathways or regulatory alternatives to minimize clinical development times, and preparedness for development of vaccines.
Under clinical trials or process, interestingly, Cohen targets ECs and IRB inefficiencies, promotes eSource Data Capture and the enforced use of common data standards, such as those created by CDISC.
Under pathways, Cohen believes an adaptive licensing approach similar to the EMA pilots now underway, would be helpful for FDA in regard to vaccine development.
Dr. Cohen is an infectious diseases expert and head’s Quintiles’ Phase I Clinical Research division, which includes world-class facilities in Overland Park, Kansas (US) and London.
Read the full release
The following infographic was sent with the press release. (Click to enlarge).
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
3
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
4
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
5